title: Liver lectin blocking with D-galactose to prevent hepatic metastases in colorectal carcinoma patients.
abstract: Animal experiments in BALB/c-mice and in DBA/2-mice confirmed that lectin blockade with D-galactose containing receptor analogues can inhibit metastatic spread into the liver. The number of liver colonies of inoculated tumor cells was significantly reduced after D-galactose treatment as compared to animals of control group. Based on experimental investigations 193 colorectal carcinoma patients (UICC stages I-III) were enrolled in a prospectively randomized clinical trial. 93 patients were treated perioperatively with D-galactose- (treatment group: 1.5 g/kg body weight and per day) or D-glucose containing electrolyte infusions (control group: n = 100). Significant side effects were not observed. There were no cases of perioperative mortality. The overall complication rate was 7.3%. Since tumor stages were unequally distributed, analysis was performed in strata. Patients were observed for a total of 6237 months. Differences in overall survival and survival free of recurrence and hepatic metastases were negligible for stages I and II. For stage III carcinoma patients (n = 75) analysis of survival free of hepatic metastases revealed a shift to delayed events (i.e. hepatic metastases or death) after D-galactose treatment within 24 months following surgery. In patients with stage III carcinoma there was an indication for an overall benefit in survival after D-galactose treatment (p = 0.102).
authors.affiliation: Clinics and Policlinics for Surgery, University Cologne, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Isenberg
authors.forename: B
authors.initials: B
authors.lastname: Stoffel
authors.forename: H
authors.initials: H
authors.lastname: Stützer
authors.forename: K
authors.initials: K
authors.lastname: Otte
authors.forename: J
authors.initials: J
authors.lastname: Beuth
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D003110:Colonic Neoplasms / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D005690:Galactose / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D037102:Lectins / Q000037:antagonists & inhibitors*; D008099:Liver / Q000737:chemistry; D008113:Liver Neoplasms / Q000401:mortality / Q000517:prevention & control* / Q000556:secondary*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D009367:Neoplasm Staging; D011446:Prospective Studies; D012004:Rectal Neoplasms / Q000401:mortality / Q000473:pathology*
chemical_list: D037102:Lectins; D005690:Galactose